首页 > 最新文献

Contemporary Oncology最新文献

英文 中文
Understanding the purpose of treatment and expectations in patients with inoperable lung cancer treated with palliative chemotherapy 姑息性化疗对不能手术肺癌患者的治疗目的和期望
Pub Date : 2015-09-28 DOI: 10.5114/wo.2015.53249
A. Nowicki, K. Woźniak, M. Krajnik
Aim of the study Informing cancer patients about various types of treatment and their adverse effects and communicating negative information is an important element of diagnostic and therapeutic procedures. Understanding the purpose of treatment and expectations, and socio-demographic factors in patients undergoing palliative chemotherapy because of lung cancer. Material and methods The study included 100 patients with lung cancer at the age of 40–80 years (mean 63.1) in the Oncology Center in Bydgoszcz in 2013–2014. The diagnostic survey method with the author's questionnaire was used. Results Forty-one percent of patients were convinced that the purpose of chemotherapy is to cure the disease. Both inhabitants of small towns (population below 50 thousand) and large villages (p = 0.09) were similarly convinced about the effectiveness of chemotherapy. Seventy-three percent of inhabitants of small towns and 79% of country dwellers (p = 0.005) thought that chemotherapy is aimed at improving the quality of life. Patients with very good economic conditions responded that chemotherapy is designed to improve the quality of life more often than those with good and bad economic conditions, 90%, 88% and 60%, respectively (p = 0.001). With the increase in population the number of people who claimed that palliative chemotherapy prolongs their life increased, 71%, 77% and 90%, respectively (p = 0.03). Conclusions The knowledge of patients with lung cancer about palliative chemotherapy is insufficient. Almost half of them do not understand the purpose of treatment and hope that chemotherapy will cure them of the disease. Most patients know that the aim of chemotherapy is to alleviate symptoms and improve quality of life and prolong their life. Half of the patients want to obtain information on treatment and half of them about life expectancy. Almost half of the patients feel stress and anxiety towards chemotherapy. Most patients do not use the help of a psychologist and do not feel such a need.
研究目的告知癌症患者各种类型的治疗及其副作用,并传达负面信息是诊断和治疗程序的重要组成部分。了解肺癌患者接受姑息性化疗的治疗目的和期望,以及社会人口因素。材料与方法本研究纳入2013-2014年Bydgoszcz肿瘤中心100例40-80岁肺癌患者(平均63.1岁)。采用作者问卷的诊断性调查方法。结果41%的患者确信化疗的目的是治愈疾病。小城镇(人口低于5万人)和大村庄(p = 0.09)的居民同样相信化疗的有效性。73%的小城镇居民和79%的农村居民(p = 0.005)认为化疗的目的是提高生活质量。经济条件非常好的患者比经济条件较好的和经济条件较差的患者更多地反映化疗旨在改善生活质量,分别为90%、88%和60% (p = 0.001)。随着人口的增加,认为姑息性化疗延长其生命的人数分别增加了71%、77%和90% (p = 0.03)。结论肺癌患者对姑息性化疗认识不足。几乎一半的人不明白治疗的目的,希望化疗能治愈他们的疾病。大多数患者都知道化疗的目的是缓解症状,改善生活质量,延长生命。一半的病人想获得治疗方面的信息,一半想获得预期寿命方面的信息。几乎一半的患者对化疗感到压力和焦虑。大多数病人不需要心理学家的帮助,也不觉得有这种需要。
{"title":"Understanding the purpose of treatment and expectations in patients with inoperable lung cancer treated with palliative chemotherapy","authors":"A. Nowicki, K. Woźniak, M. Krajnik","doi":"10.5114/wo.2015.53249","DOIUrl":"https://doi.org/10.5114/wo.2015.53249","url":null,"abstract":"Aim of the study Informing cancer patients about various types of treatment and their adverse effects and communicating negative information is an important element of diagnostic and therapeutic procedures. Understanding the purpose of treatment and expectations, and socio-demographic factors in patients undergoing palliative chemotherapy because of lung cancer. Material and methods The study included 100 patients with lung cancer at the age of 40–80 years (mean 63.1) in the Oncology Center in Bydgoszcz in 2013–2014. The diagnostic survey method with the author's questionnaire was used. Results Forty-one percent of patients were convinced that the purpose of chemotherapy is to cure the disease. Both inhabitants of small towns (population below 50 thousand) and large villages (p = 0.09) were similarly convinced about the effectiveness of chemotherapy. Seventy-three percent of inhabitants of small towns and 79% of country dwellers (p = 0.005) thought that chemotherapy is aimed at improving the quality of life. Patients with very good economic conditions responded that chemotherapy is designed to improve the quality of life more often than those with good and bad economic conditions, 90%, 88% and 60%, respectively (p = 0.001). With the increase in population the number of people who claimed that palliative chemotherapy prolongs their life increased, 71%, 77% and 90%, respectively (p = 0.03). Conclusions The knowledge of patients with lung cancer about palliative chemotherapy is insufficient. Almost half of them do not understand the purpose of treatment and hope that chemotherapy will cure them of the disease. Most patients know that the aim of chemotherapy is to alleviate symptoms and improve quality of life and prolong their life. Half of the patients want to obtain information on treatment and half of them about life expectancy. Almost half of the patients feel stress and anxiety towards chemotherapy. Most patients do not use the help of a psychologist and do not feel such a need.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"36 1","pages":"333 - 337"},"PeriodicalIF":0.0,"publicationDate":"2015-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87173012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial 波兰晚期braf阳性黑色素瘤患者接受vemurafenib治疗的安全性临床试验结果
Pub Date : 2015-09-28 DOI: 10.5114/wo.2015.54082
P. Rutkowski, K. Kozak, J. Mackiewicz, K. Krzemieniecki, S. Nawrocki, E. Wasilewska-Teśluk, Łukasz Kwinta, P. Wysocki, H. Koseła-Paterczyk, T. Świtaj
Aim of the study The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Polish oncological centres. Material and methods Patients with untreated or previously treated Stage IIIC/IV BRAFV600 mutation-positive melanoma were treated with oral vemurafenib in an initial dose of 960 mg twice daily. Assessments for safety and efficacy were made every 28 days. For the survival analysis the Kaplan-Meier estimator was used with the log-rank tests for bivariate comparisons. Results In total, 75 Polish patients were enrolled in the safety study across four centres. At data cut-off, 28 patients died (37%), mainly (26) due to disease progression; 33 (44%) patients continued vemurafenib after disease progression. The objective response rate was 46%, including two patients with a complete response and 29 with a partial response. Median progression-free survival was 7.4 months. The one-year overall survival rate was 61.9% (median overall survival was not reached). Seventy-three (97.3%) patients reported adverse events (AEs), and grade 3–5 toxicity was reported in 49.4% (37) patients. The most common AEs were: skin lesions (including rash and photosensitivity), arthralgia, and fatigue. Conclusions The overall safety profile and response rate of vemurafenib were comparable to those reported in previous studies of this drug. Our study confirmed the value of well-established prognostic features for overall survival, such as initial LDH (lactate dehydrogenase) level and AJCC staging.
BRAF抑制剂vemurafenib可改善brafv600突变阳性转移性黑色素瘤患者的无进展生存期和总生存期。在此,我们介绍了在波兰肿瘤中心登记的转移性黑色素瘤患者中使用vemurafenib的一项开放标签安全性研究的结果。材料和方法未经治疗或先前治疗过的IIIC/IV期BRAFV600突变阳性黑色素瘤患者口服vemurafenib,初始剂量为960 mg,每日2次。每28天进行一次安全性和有效性评估。对于生存分析,Kaplan-Meier估计量与双变量比较的log-rank检验一起使用。结果:共有75名波兰患者参加了4个中心的安全性研究。截止数据时,28例(37%)患者死亡,主要(26例)由于疾病进展;33例(44%)患者在疾病进展后继续服用vemurafenib。客观缓解率为46%,包括2例完全缓解和29例部分缓解。中位无进展生存期为7.4个月。1年总生存率为61.9%(未达到中位总生存率)。73例(97.3%)患者报告了不良事件(ae), 49.4%(37)患者报告了3-5级毒性。最常见的ae是:皮肤损伤(包括皮疹和光敏性)、关节痛和疲劳。结论:vemurafenib的总体安全性和反应率与该药物的先前研究报告相当。我们的研究证实了既定的预后特征对总体生存的价值,如初始LDH(乳酸脱氢酶)水平和AJCC分期。
{"title":"The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial","authors":"P. Rutkowski, K. Kozak, J. Mackiewicz, K. Krzemieniecki, S. Nawrocki, E. Wasilewska-Teśluk, Łukasz Kwinta, P. Wysocki, H. Koseła-Paterczyk, T. Świtaj","doi":"10.5114/wo.2015.54082","DOIUrl":"https://doi.org/10.5114/wo.2015.54082","url":null,"abstract":"Aim of the study The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Polish oncological centres. Material and methods Patients with untreated or previously treated Stage IIIC/IV BRAFV600 mutation-positive melanoma were treated with oral vemurafenib in an initial dose of 960 mg twice daily. Assessments for safety and efficacy were made every 28 days. For the survival analysis the Kaplan-Meier estimator was used with the log-rank tests for bivariate comparisons. Results In total, 75 Polish patients were enrolled in the safety study across four centres. At data cut-off, 28 patients died (37%), mainly (26) due to disease progression; 33 (44%) patients continued vemurafenib after disease progression. The objective response rate was 46%, including two patients with a complete response and 29 with a partial response. Median progression-free survival was 7.4 months. The one-year overall survival rate was 61.9% (median overall survival was not reached). Seventy-three (97.3%) patients reported adverse events (AEs), and grade 3–5 toxicity was reported in 49.4% (37) patients. The most common AEs were: skin lesions (including rash and photosensitivity), arthralgia, and fatigue. Conclusions The overall safety profile and response rate of vemurafenib were comparable to those reported in previous studies of this drug. Our study confirmed the value of well-established prognostic features for overall survival, such as initial LDH (lactate dehydrogenase) level and AJCC staging.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"46 1","pages":"280 - 283"},"PeriodicalIF":0.0,"publicationDate":"2015-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81081331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Changing incidence of esophageal cancer among white women: analysis of SEER data (1992–2010) 白人女性食管癌发病率的变化:1992-2010年SEER数据分析
Pub Date : 2015-09-28 DOI: 10.5114/wo.2015.54390
R. Raman, S. Deorah, Bradley D. McDowell, T. A. Hejleh, C. Lynch, Amit K. Gupta
Aim of the study To analyse trends in the incidence rates of adenocarcinoma and squamous cell carcinoma of the oesophagus (ACE and SCC, respectively) in white women between 1992 and 2010. Material and methods We used data from the Surveillance, Epidemiology, and End Results (SEER program to identify cases of esophageal cancer). Age adjusted incidence rates (IR) were calculated for ACE and SCC for two different time periods (1992–1996 and 2006–2010) and stratified by age, stage, and histologic type. We used joinpoint analysis to detect changes in rates between 1992 and 2010. Results Between the time periods 1992–1996 and 2006–2010, the age-adjusted incidence rates for SCC in white women decreased from 1.2/100,000 to 0.8/100,000 personyears, and for ACE it increased from 0.5/100,000 to 0.7/100,000 personyears. Similar to white men, the increase in the incidence of ACE was consistent for all stages and all age groups in white women. However, it was most pronounced in women aged 45–59 years, where the incidence of ACE (0.9/100,000 person-years) in 2006–2010 exceeded the incidence of SCC (0.6/100,000 person-years). On joinpoint regression analysis, an inflection point was seen in 1999 for ACE, indicating a slower rate of increase for ACE after 1999 (annual percentage change of 8.00 before 1999 vs. 0.88 starting in 1999). Conclusions The incidence of ACE is increasing in white women, irrespective of age or stage. Indeed, ACE is now more common than SCC in white women between 45 and 59 years of age.
研究目的:分析1992年至2010年间白人女性食管腺癌和鳞状细胞癌(ACE和SCC)发病率的变化趋势。材料和方法我们使用来自监测、流行病学和最终结果(SEER项目)的数据来确定食管癌病例。计算两个不同时期(1992-1996年和2006-2010年)ACE和SCC的年龄调整发病率(IR),并按年龄、分期和组织学类型分层。我们使用连接点分析来检测1992年至2010年间的比率变化。结果1992-1996年和2006-2010年期间,白人女性SCC的年龄调整发病率从1.2/10万下降到0.8/10万,ACE从0.5/10万上升到0.7/10万。与白人男性相似,ACE发生率的增加在白人女性的所有阶段和所有年龄组中都是一致的。然而,在45-59岁的女性中最为明显,2006-2010年ACE的发病率(0.9/10万人年)超过了SCC的发病率(0.6/10万人年)。在联合点回归分析中,1999年出现了ACE的拐点,表明1999年之后ACE的增长速度较慢(1999年之前的年百分比变化为8.00,而1999年开始的年百分比变化为0.88)。结论:ACE在白人女性中的发病率呈上升趋势,与年龄和分期无关。事实上,在45岁至59岁的白人女性中,ACE比SCC更常见。
{"title":"Changing incidence of esophageal cancer among white women: analysis of SEER data (1992–2010)","authors":"R. Raman, S. Deorah, Bradley D. McDowell, T. A. Hejleh, C. Lynch, Amit K. Gupta","doi":"10.5114/wo.2015.54390","DOIUrl":"https://doi.org/10.5114/wo.2015.54390","url":null,"abstract":"Aim of the study To analyse trends in the incidence rates of adenocarcinoma and squamous cell carcinoma of the oesophagus (ACE and SCC, respectively) in white women between 1992 and 2010. Material and methods We used data from the Surveillance, Epidemiology, and End Results (SEER program to identify cases of esophageal cancer). Age adjusted incidence rates (IR) were calculated for ACE and SCC for two different time periods (1992–1996 and 2006–2010) and stratified by age, stage, and histologic type. We used joinpoint analysis to detect changes in rates between 1992 and 2010. Results Between the time periods 1992–1996 and 2006–2010, the age-adjusted incidence rates for SCC in white women decreased from 1.2/100,000 to 0.8/100,000 personyears, and for ACE it increased from 0.5/100,000 to 0.7/100,000 personyears. Similar to white men, the increase in the incidence of ACE was consistent for all stages and all age groups in white women. However, it was most pronounced in women aged 45–59 years, where the incidence of ACE (0.9/100,000 person-years) in 2006–2010 exceeded the incidence of SCC (0.6/100,000 person-years). On joinpoint regression analysis, an inflection point was seen in 1999 for ACE, indicating a slower rate of increase for ACE after 1999 (annual percentage change of 8.00 before 1999 vs. 0.88 starting in 1999). Conclusions The incidence of ACE is increasing in white women, irrespective of age or stage. Indeed, ACE is now more common than SCC in white women between 45 and 59 years of age.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"52 1","pages":"338 - 340"},"PeriodicalIF":0.0,"publicationDate":"2015-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74979818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma 卵巢癌患者血液和腹水中不同细胞毒性细胞亚群的比较研究
Pub Date : 2015-09-18 DOI: 10.5114/wo.2015.54388
Š. Lukešová, V. Vroblová, J. Tošner, J. Kopecký, I. Sedláková, E. Cermakova, D. Vokurková, O. Kopecký
Aim of the study A number of observations have indicated that the immune system plays a significant role in patients with epithelial ovarian cancer (EOC). In cases of EOC, the prognostic significance of tumour infiltrating lymphocytes has not been clearly explained yet. The aim is to determine the phenotype and activation molecules of cytotoxic T cell and NK cell subpopulations and to compare their representation in malignant ascites and peripheral blood in patients with ovarian cancer. Material and methods Cytotoxic cells taken from blood samples of the cubital vein and malignant ascites were obtained from 53 patients with EOC. Their surface and activation characteristics were determined by means of a flow cytometer. Immunophenotype multiparametric analysis of peripheral blood lymphocytes (PBLs) and tumour infiltrating lymphocytes (TILs) was carried out. Results CD3+ T lymphocytes were the main population of TILs (75.9%) and PBLs (70.9%). The number of activating T cells was significantly higher in TILs: CD3+/69+ 6.7% vs. 0.8% (p < 0.001). The representation of (CD3–/16+56+) NK cells in TILs was significantly higher: 11.0% vs. 5.6% (p = 0.041); likewise CD56bright and CD–56bright from CD56+ cells were higher in TILs (both p < 0.001). The activation receptor NKG2D was present in 45.1% of TILs vs. 32.3% of PBLs (p = 0.034), but we did not find a significant difference in the numbers of CD56+/NKG2D+ in TILs and PBLs. Conclusions These results prove that the characteristics and intensity of anti-tumour responses are different in compared compartments (ascites/PBLs). The knowledge of phenotype and functions of effector cells is the basic precondition for understanding the anti-tumour immune response.
研究目的许多观察结果表明,免疫系统在上皮性卵巢癌(EOC)患者中起着重要作用。在EOC病例中,肿瘤浸润淋巴细胞的预后意义尚未明确解释。目的是确定细胞毒性T细胞和NK细胞亚群的表型和激活分子,并比较它们在卵巢癌患者恶性腹水和外周血中的表现。材料与方法对53例EOC患者的肘静脉及恶性腹水血样进行细胞毒细胞检测。用流式细胞仪测定其表面和活化特性。外周血淋巴细胞(pbl)和肿瘤浸润淋巴细胞(TILs)的免疫表型多参数分析。结果TILs(75.9%)和pbl(70.9%)以CD3+ T淋巴细胞为主。激活T细胞的数量在TILs中显著增加:CD3+/69+ 6.7% vs. 0.8% (p < 0.001)。(CD3 - /16+56+) NK细胞在TILs中的代表性显著高于前者:11.0% vs. 5.6% (p = 0.041);同样,CD56+细胞的CD56bright和CD-56bright在TILs中也较高(p < 0.001)。激活受体NKG2D存在于45.1%的TILs和32.3%的pbl中(p = 0.034),但我们没有发现TILs和pbl中CD56+/NKG2D+的数量有显著差异。结论腹水/ pbl间室抗肿瘤反应的特点和强度不同。了解效应细胞的表型和功能是了解抗肿瘤免疫应答的基本前提。
{"title":"Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma","authors":"Š. Lukešová, V. Vroblová, J. Tošner, J. Kopecký, I. Sedláková, E. Cermakova, D. Vokurková, O. Kopecký","doi":"10.5114/wo.2015.54388","DOIUrl":"https://doi.org/10.5114/wo.2015.54388","url":null,"abstract":"Aim of the study A number of observations have indicated that the immune system plays a significant role in patients with epithelial ovarian cancer (EOC). In cases of EOC, the prognostic significance of tumour infiltrating lymphocytes has not been clearly explained yet. The aim is to determine the phenotype and activation molecules of cytotoxic T cell and NK cell subpopulations and to compare their representation in malignant ascites and peripheral blood in patients with ovarian cancer. Material and methods Cytotoxic cells taken from blood samples of the cubital vein and malignant ascites were obtained from 53 patients with EOC. Their surface and activation characteristics were determined by means of a flow cytometer. Immunophenotype multiparametric analysis of peripheral blood lymphocytes (PBLs) and tumour infiltrating lymphocytes (TILs) was carried out. Results CD3+ T lymphocytes were the main population of TILs (75.9%) and PBLs (70.9%). The number of activating T cells was significantly higher in TILs: CD3+/69+ 6.7% vs. 0.8% (p < 0.001). The representation of (CD3–/16+56+) NK cells in TILs was significantly higher: 11.0% vs. 5.6% (p = 0.041); likewise CD56bright and CD–56bright from CD56+ cells were higher in TILs (both p < 0.001). The activation receptor NKG2D was present in 45.1% of TILs vs. 32.3% of PBLs (p = 0.034), but we did not find a significant difference in the numbers of CD56+/NKG2D+ in TILs and PBLs. Conclusions These results prove that the characteristics and intensity of anti-tumour responses are different in compared compartments (ascites/PBLs). The knowledge of phenotype and functions of effector cells is the basic precondition for understanding the anti-tumour immune response.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"35 1","pages":"290 - 299"},"PeriodicalIF":0.0,"publicationDate":"2015-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76647085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
Dietary habits of lung cancer patients from the Lower Silesia region of Poland 波兰下西里西亚地区肺癌患者的饮食习惯
Pub Date : 2015-09-16 DOI: 10.5114/wo.2015.54084
K. Zabłocka-Słowińska, I. Porębska, M. Gołecki, A. Prescha, J. Pieczyńska, M. Kosacka, R. Ilow, H. Grajeta, R. Jankowska, J. Biernat
Aim of the study Assessment of lung cancer patients’ dietary habits before treatment enable medical staff to provide more individual, precise and complex care to patients, taking into consideration their nutritional status. The aim of this study was, therefore, to evaluate dietary habits related to lung cancer risk of lung cancer patients in comparison with controls from the Lower Silesia region of Poland. Material and methods Assessments of dietary habits, based on a validated questionnaire related to lung cancer risk were performed on 92 lung cancer patients and compared with the results obtained in 157 controls. Dietary patterns were evaluated concerning on eating frequency of high- and low- glycemic index products, vegetables and fruits, vegetable and fruit juices, green tea, liquid dairy products, meat and fried products over the previous year. Alcohol consumption was assessed on a dichotomous scale (yes or no). Results Majority of patients had inappropriate dietary habits, such as low consumption of low GI cereal products, vegetables, fruit and green tea, and a high consumption frequency of fried products. Conclusions Reported dietary mistakes indicate the need for dietary education among people at lung cancer risk and with newly diagnosed disease, to enhance their nutritional status.
研究目的:对肺癌患者治疗前的饮食习惯进行评估,使医护人员能够根据患者的营养状况,为患者提供更个性化、更精准、更复杂的护理。因此,本研究的目的是评估与肺癌患者肺癌风险相关的饮食习惯,并与波兰下西里西亚地区的对照组进行比较。材料与方法基于一份与肺癌风险相关的有效问卷,对92名肺癌患者的饮食习惯进行了评估,并与157名对照组的结果进行了比较。在过去的一年里,对饮食模式进行了评估,包括高和低血糖指数产品、蔬菜和水果、蔬菜和果汁、绿茶、液态乳制品、肉类和油炸食品的食用频率。酒精消费以二分法评估(是或否)。结果多数患者饮食习惯不适宜,低GI谷物制品、蔬菜、水果、绿茶摄取量低,油炸食品摄取量高。结论报告的饮食错误提示有必要对肺癌高危人群和新诊断疾病人群进行饮食教育,以改善他们的营养状况。
{"title":"Dietary habits of lung cancer patients from the Lower Silesia region of Poland","authors":"K. Zabłocka-Słowińska, I. Porębska, M. Gołecki, A. Prescha, J. Pieczyńska, M. Kosacka, R. Ilow, H. Grajeta, R. Jankowska, J. Biernat","doi":"10.5114/wo.2015.54084","DOIUrl":"https://doi.org/10.5114/wo.2015.54084","url":null,"abstract":"Aim of the study Assessment of lung cancer patients’ dietary habits before treatment enable medical staff to provide more individual, precise and complex care to patients, taking into consideration their nutritional status. The aim of this study was, therefore, to evaluate dietary habits related to lung cancer risk of lung cancer patients in comparison with controls from the Lower Silesia region of Poland. Material and methods Assessments of dietary habits, based on a validated questionnaire related to lung cancer risk were performed on 92 lung cancer patients and compared with the results obtained in 157 controls. Dietary patterns were evaluated concerning on eating frequency of high- and low- glycemic index products, vegetables and fruits, vegetable and fruit juices, green tea, liquid dairy products, meat and fried products over the previous year. Alcohol consumption was assessed on a dichotomous scale (yes or no). Results Majority of patients had inappropriate dietary habits, such as low consumption of low GI cereal products, vegetables, fruit and green tea, and a high consumption frequency of fried products. Conclusions Reported dietary mistakes indicate the need for dietary education among people at lung cancer risk and with newly diagnosed disease, to enhance their nutritional status.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"20 1","pages":"391 - 395"},"PeriodicalIF":0.0,"publicationDate":"2015-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76750623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience 185例who定义的原发性血小板增多症患者的血栓风险评估:单中心经验
Pub Date : 2015-09-16 DOI: 10.5114/wo.2015.54083
R. Dambrauskienė, R. Gerbutavičius, E. Juozaitytė, R. Gerbutavičienė
Thrombosis risk in essential thrombocythemia (ET) patients can be assessed using different prognostic systems. Conventional risk factors include age more than 60 years and history of previous thrombosis. In addition, other factors such as JAK2 V617F mutations, cardiovascular risk factors, leukocytosis more than 11 × 109/l, thrombophilic factors and platelet count more than 1500 × 109/l are used in different hematology centers as high-risk features for thrombosis. Our study compared different risk model groups for thrombosis in 185 WHO-defined ET patients at the Hospital of Lithuanian University of Health Sciences Kaunas Klinikos. We found that patient distribution in low, intermediate- and high-risk groups varies using different risk stratification models. The biggest difference in risk assignment is evident in patients who are older than 60 years and have no other risk factors and in patients who are younger than 60 years but have other risk factors. This observation suggests that new prospective randomized clinical trials are needed to better stratify patients at risk for thrombosis.
原发性血小板增多症(ET)患者的血栓形成风险可以使用不同的预后系统进行评估。传统的危险因素包括60岁以上的年龄和既往血栓病史。此外,JAK2 V617F突变、心血管危险因素、白细胞超过11 × 109/l、嗜血栓因子、血小板超过1500 × 109/l等其他因素被不同血液学中心作为血栓形成的高危特征。我们的研究比较了立陶宛Kaunas Klinikos卫生科学大学医院185名who定义的ET患者血栓形成的不同风险模型组。我们发现,使用不同的风险分层模型,低、中、高风险组的患者分布各不相同。在年龄大于60岁且没有其他危险因素的患者和年龄小于60岁但有其他危险因素的患者中,风险分配的最大差异是明显的。这一观察结果表明,需要新的前瞻性随机临床试验来更好地对血栓形成风险患者进行分层。
{"title":"Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience","authors":"R. Dambrauskienė, R. Gerbutavičius, E. Juozaitytė, R. Gerbutavičienė","doi":"10.5114/wo.2015.54083","DOIUrl":"https://doi.org/10.5114/wo.2015.54083","url":null,"abstract":"Thrombosis risk in essential thrombocythemia (ET) patients can be assessed using different prognostic systems. Conventional risk factors include age more than 60 years and history of previous thrombosis. In addition, other factors such as JAK2 V617F mutations, cardiovascular risk factors, leukocytosis more than 11 × 109/l, thrombophilic factors and platelet count more than 1500 × 109/l are used in different hematology centers as high-risk features for thrombosis. Our study compared different risk model groups for thrombosis in 185 WHO-defined ET patients at the Hospital of Lithuanian University of Health Sciences Kaunas Klinikos. We found that patient distribution in low, intermediate- and high-risk groups varies using different risk stratification models. The biggest difference in risk assignment is evident in patients who are older than 60 years and have no other risk factors and in patients who are younger than 60 years but have other risk factors. This observation suggests that new prospective randomized clinical trials are needed to better stratify patients at risk for thrombosis.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"92 1","pages":"396 - 399"},"PeriodicalIF":0.0,"publicationDate":"2015-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83100440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study 尿嘧啶/替加氟作为化疗难治性结直肠癌患者可能的补救性治疗:一项单一机构回顾性研究
Pub Date : 2015-08-13 DOI: 10.5114/wo.2015.53374
I. V. Bayoglu, I. Yıldız, U. Varol, S. Çokmert, A. Alacacıoğlu, Y. Kucukzeybek, M. Akyol, L. Demir, A. Dirican, O. Tarhan
Aim of the study Our aim was to determine the activity and toxicity of uracil/tegafur and leucovorin combination in metastatic colorectal cancer (mCRC) patients who have progressed with all currently active agents. Material and methods This study was a retrospective analysis of 50 mCRC patients who had previously failed to respond to all available chemotherapeutics and who received subsequent treatment with uracil/tegafur 250 mg/m2 d1–5 in combination with leucovorin 90 mg/day, d1–5 followed by two days’ rest. Results The median age of the patients was 60 years. Most of them (60%) were male. Bevacizumab was used in 65% and cetuximab in 55% of the patients. Thirty-nine patients (78%) were treated with uracil/tegafur in the fourth line setting. The median treatment duration was 4.2 months (range, 2–24 months). The objective response rate and the disease control rate were 4% and 34%, respectively. Median progression-free survival was 4.1 months (95% CI, 3.6–4.6 months) and overall survival was 6.6 months (95% CI, 4.5–8.6 months). Grade 3 or 4 toxicity was seen in 20% (n = 10) of the patients while 60% (n = 6) of them required dose reductions. Conclusions This retrospective data show that uracil/tegafur may be considered in heavily pretreated mCRC patients because of its activity, lower toxicity, and feasibility.
我们的目的是确定尿嘧啶/替加富和亚叶酸蛋白联合治疗进展的转移性结直肠癌(mCRC)患者的活性和毒性。材料和方法本研究回顾性分析了50例既往化疗无效的mCRC患者,这些患者随后接受了尿嘧啶/替加富250mg /m2 d1-5联合亚叶酸素90mg /d, d1-5,随后休息2天。结果患者中位年龄60岁。其中大多数(60%)是男性。65%的患者使用贝伐单抗,55%的患者使用西妥昔单抗。39名患者(78%)在第四线环境中接受尿嘧啶/替加富治疗。中位治疗时间为4.2个月(范围2-24个月)。客观有效率为4%,疾病控制率为34%。中位无进展生存期为4.1个月(95% CI, 3.6-4.6个月),总生存期为6.6个月(95% CI, 4.5-8.6个月)。20% (n = 10)的患者出现3级或4级毒性,60% (n = 6)的患者需要减少剂量。结论本回顾性数据显示,由于尿嘧啶/替加富的活性、低毒性和可行性,可能被考虑用于重度预处理的mCRC患者。
{"title":"Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study","authors":"I. V. Bayoglu, I. Yıldız, U. Varol, S. Çokmert, A. Alacacıoğlu, Y. Kucukzeybek, M. Akyol, L. Demir, A. Dirican, O. Tarhan","doi":"10.5114/wo.2015.53374","DOIUrl":"https://doi.org/10.5114/wo.2015.53374","url":null,"abstract":"Aim of the study Our aim was to determine the activity and toxicity of uracil/tegafur and leucovorin combination in metastatic colorectal cancer (mCRC) patients who have progressed with all currently active agents. Material and methods This study was a retrospective analysis of 50 mCRC patients who had previously failed to respond to all available chemotherapeutics and who received subsequent treatment with uracil/tegafur 250 mg/m2 d1–5 in combination with leucovorin 90 mg/day, d1–5 followed by two days’ rest. Results The median age of the patients was 60 years. Most of them (60%) were male. Bevacizumab was used in 65% and cetuximab in 55% of the patients. Thirty-nine patients (78%) were treated with uracil/tegafur in the fourth line setting. The median treatment duration was 4.2 months (range, 2–24 months). The objective response rate and the disease control rate were 4% and 34%, respectively. Median progression-free survival was 4.1 months (95% CI, 3.6–4.6 months) and overall survival was 6.6 months (95% CI, 4.5–8.6 months). Grade 3 or 4 toxicity was seen in 20% (n = 10) of the patients while 60% (n = 6) of them required dose reductions. Conclusions This retrospective data show that uracil/tegafur may be considered in heavily pretreated mCRC patients because of its activity, lower toxicity, and feasibility.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"66 1","pages":"385 - 390"},"PeriodicalIF":0.0,"publicationDate":"2015-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87654503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The effect of Lactobacillus casei extract on cervical cancer cell lines 干酪乳杆菌提取物对宫颈癌细胞系的影响
Pub Date : 2015-08-13 DOI: 10.5114/wo.2014.45292
Soo‐Nyung Kim, Won Moo Lee, Kyoung Sik Park, Jong Bin Kim, D. Han, J. Bae
Aim of the study Lactobacillus casei (L. casei) has been shown to inhibit the proliferation of several types of cancer in vivo, but its effect on cervical cells has not been reported. We incubated cells of the human cervical cell lines Caski and HeLa with extracts of L. casei and investigated its effects on the growth of the cells and possible synergy with anticancer drugs. Material and methods Cell-free extracts of L. casei were prepared and purified. Cultures of Caski and HeLa cells adhering to tissue culture plates were treated with L. casei extract. The effects of L. casei extract on the growth of cancer cells and its possible synergy with anti-cancer drugs in cervical cancer cell lines were investigated. The cells were treated with L. casei extract alone, anti-cancer drugs alone [doxorubicin, paclitaxel, 5-fluorouracil (5-FU), and cisplatin], or L. casei extract plus anti-cancer drugs. Results L. casei extract had no significant effect on the growth rate of the two cell lines. Anti-cancer drugs alone induced growth inhibition, but there was no synergistic effect of L. casei extract on growth inhibition. Conclusions L. casei extract does not have a potent effect on the viability of cervical cancer cells in vitro. In addition, L. casei extract has no synergistic effect on the inhibition of growth of cancer cells in the presence of anti-cancer drugs.
研究目的:干酪乳杆菌(Lactobacillus casei, L. casei)在体内已被证明能抑制几种癌症的增殖,但其对宫颈细胞的作用尚未见报道。用干酪乳杆菌提取物培养人宫颈细胞系Caski和HeLa细胞,研究其对细胞生长的影响及其与抗癌药物的协同作用。材料与方法制备并纯化干酪乳杆菌无细胞提取物。Caski和HeLa细胞粘附于组织培养板上,用干酪乳杆菌提取物处理。研究了干酪乳杆菌提取物对宫颈癌细胞生长的影响及其与抗癌药物的协同作用。分别用干酪乳杆菌提取物、单用抗癌药物[阿霉素、紫杉醇、5-氟尿嘧啶、顺铂]或干酪乳杆菌提取物联合抗癌药物治疗。结果干酪乳杆菌提取物对两种细胞株的生长均无显著影响。单用抗癌药物可抑制肿瘤生长,而干酪乳杆菌提取物对肿瘤生长无协同抑制作用。结论干酪乳杆菌提取物对体外培养的宫颈癌细胞活力无明显影响。此外,在抗癌药物存在的情况下,干酪乳杆菌提取物对癌细胞生长的抑制没有协同作用。
{"title":"The effect of Lactobacillus casei extract on cervical cancer cell lines","authors":"Soo‐Nyung Kim, Won Moo Lee, Kyoung Sik Park, Jong Bin Kim, D. Han, J. Bae","doi":"10.5114/wo.2014.45292","DOIUrl":"https://doi.org/10.5114/wo.2014.45292","url":null,"abstract":"Aim of the study Lactobacillus casei (L. casei) has been shown to inhibit the proliferation of several types of cancer in vivo, but its effect on cervical cells has not been reported. We incubated cells of the human cervical cell lines Caski and HeLa with extracts of L. casei and investigated its effects on the growth of the cells and possible synergy with anticancer drugs. Material and methods Cell-free extracts of L. casei were prepared and purified. Cultures of Caski and HeLa cells adhering to tissue culture plates were treated with L. casei extract. The effects of L. casei extract on the growth of cancer cells and its possible synergy with anti-cancer drugs in cervical cancer cell lines were investigated. The cells were treated with L. casei extract alone, anti-cancer drugs alone [doxorubicin, paclitaxel, 5-fluorouracil (5-FU), and cisplatin], or L. casei extract plus anti-cancer drugs. Results L. casei extract had no significant effect on the growth rate of the two cell lines. Anti-cancer drugs alone induced growth inhibition, but there was no synergistic effect of L. casei extract on growth inhibition. Conclusions L. casei extract does not have a potent effect on the viability of cervical cancer cells in vitro. In addition, L. casei extract has no synergistic effect on the inhibition of growth of cancer cells in the presence of anti-cancer drugs.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"87 1","pages":"306 - 312"},"PeriodicalIF":0.0,"publicationDate":"2015-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83446056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Aromatase inhibitor treatment for breast cancer: short-term effect on bone health 芳香酶抑制剂治疗乳腺癌:对骨骼健康的短期影响
Pub Date : 2015-08-07 DOI: 10.5114/wo.2014.45305
G. Erbag, K. Uygun, E. Binnetoğlu, A. Korkmaz, M. Aşık, H. Şen, F. Güneş, M. Eroğlu, F. Gökmen, S. Temiz
Aim of this study Aim of this study was to examine the effects of aromatase inhibitors (AIs), which are used in every phase of breast cancer treatment, on the bone mineral density (BMD) of patients with early-stage breast cancer. Material and methods Menopausal female patients who were diagnosed with stages 1–3 breast cancer and who were planned for anastrazole or letrozole as adjuvant therapy were examined. After the patients’ BMD was measured, 45 patients without osteoporosis were included in the study. Six months after AI therapy started, the patients’ BMD was measured again. Results In this study, we tried to show that there was a statistical difference in the BMD of 45 patients before and 6 months after treatment. Among all measurements (femur and lumbar T-scores), the femur Z-score (p = 0.52) was the only score that was not statistically significant. Statistical significance (p < 0.01) was detected in comparative analysis of the other measurements. According to this analysis, a significant loss of BMD was seen even in the first six months after AI treatment was introduced. Conclusions Female patients with breast cancer are at higher risk for bone loss and fractures than healthy women. In this study, we showed the negative effects on BMD of aromatase inhibitor therapy, one of the main contributions to osteoporosis in women with breast cancer. This study is the first to quantify the short-term effect of AI treatment on BMD in postmenopausal women with breast cancer.
本研究的目的是研究芳香化酶抑制剂(AIs)对早期乳腺癌患者骨矿物质密度(BMD)的影响,芳香化酶抑制剂在乳腺癌治疗的每个阶段都被使用。材料与方法对绝经期1-3期乳腺癌患者,计划给予阿纳唑或来曲唑辅助治疗。测定患者骨密度后,纳入45例无骨质疏松症患者。人工智能治疗开始6个月后,再次测量患者的骨密度。在本研究中,我们试图证明45例患者在治疗前和治疗后6个月的BMD有统计学差异。在所有测量(股骨和腰椎t评分)中,股骨z评分(p = 0.52)是唯一无统计学意义的评分。其他指标比较分析均有统计学意义(p < 0.01)。根据这一分析,即使在引入人工智能治疗后的前6个月,骨密度也出现了显著下降。结论女性乳腺癌患者发生骨质流失和骨折的风险高于健康女性。在这项研究中,我们展示了芳香酶抑制剂治疗对骨密度的负面影响,芳香酶抑制剂治疗是乳腺癌女性骨质疏松症的主要原因之一。这项研究首次量化了人工智能治疗对绝经后乳腺癌妇女骨密度的短期影响。
{"title":"Aromatase inhibitor treatment for breast cancer: short-term effect on bone health","authors":"G. Erbag, K. Uygun, E. Binnetoğlu, A. Korkmaz, M. Aşık, H. Şen, F. Güneş, M. Eroğlu, F. Gökmen, S. Temiz","doi":"10.5114/wo.2014.45305","DOIUrl":"https://doi.org/10.5114/wo.2014.45305","url":null,"abstract":"Aim of this study Aim of this study was to examine the effects of aromatase inhibitors (AIs), which are used in every phase of breast cancer treatment, on the bone mineral density (BMD) of patients with early-stage breast cancer. Material and methods Menopausal female patients who were diagnosed with stages 1–3 breast cancer and who were planned for anastrazole or letrozole as adjuvant therapy were examined. After the patients’ BMD was measured, 45 patients without osteoporosis were included in the study. Six months after AI therapy started, the patients’ BMD was measured again. Results In this study, we tried to show that there was a statistical difference in the BMD of 45 patients before and 6 months after treatment. Among all measurements (femur and lumbar T-scores), the femur Z-score (p = 0.52) was the only score that was not statistically significant. Statistical significance (p < 0.01) was detected in comparative analysis of the other measurements. According to this analysis, a significant loss of BMD was seen even in the first six months after AI treatment was introduced. Conclusions Female patients with breast cancer are at higher risk for bone loss and fractures than healthy women. In this study, we showed the negative effects on BMD of aromatase inhibitor therapy, one of the main contributions to osteoporosis in women with breast cancer. This study is the first to quantify the short-term effect of AI treatment on BMD in postmenopausal women with breast cancer.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"116 1","pages":"374 - 377"},"PeriodicalIF":0.0,"publicationDate":"2015-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75896642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Less aggressive disease in patients with primary squamous cell carcinomas of the thyroid gland and coexisting lymphocytic thyroiditis 原发性甲状腺鳞状细胞癌合并淋巴细胞性甲状腺炎患者侵袭性较低的疾病
Pub Date : 2015-08-07 DOI: 10.5114/wo.2015.53372
M. Aşık, E. Binnetoğlu, H. Şen, F. Gunes, A. Muratlı, D. Kankaya, F. Uysal, M. Şahin, K. Ukinç
Aim of the study Primary squamous cell carcinoma (SCC) of the thyroid gland is extremely rare. Infrequently, primary SCC of the thyroid gland is accompanied by other thyroid diseases such as Hashimoto's thyroiditis (HT). Recently, studies have demonstrated that differentiated thyroid cancer with coexisting HT has a better prognosis. However, the prognosis of patients with primary SCC of the thyroid gland and coexistent HT has not been clearly identified. We compared the clinical characteristics and disease stages of patients with primary SCC with and without lymphocytic thyroiditis (LT). Material and methods We reviewed reports of primary SCC of the thyroid gland published in the English literature. Results and conclusions We identified 46 papers that included 17 cases of primary SCC of the thyroid gland with LT and 77 cases of primary SCC of the thyroid gland without LT. Lymph node metastasis and local invasion rates did not differ between these two groups. Distant metastases were absent in patients with LT, and were observed in 13 (16.9%) patients without LT. A greater proportion of patients without LT had advanced stage disease (stage IV A-B-C) than patients with LT (p < 0.05). Patients with primary SCC of the thyroid gland and coexisting LT had lower tumour-node-metastasis stage and frequency of distant metastasis than those without LT. Lymphocytic infiltration in patients with SCC appears to limit tumour growth and distant metastases.
研究目的原发性甲状腺鳞状细胞癌(SCC)极为罕见。原发性甲状腺鳞状细胞癌罕见地伴有其他甲状腺疾病,如桥本甲状腺炎(HT)。近年来研究表明分化型甲状腺癌合并HT预后较好。然而,原发性甲状腺鳞状细胞癌合并HT患者的预后尚未明确。我们比较了原发性鳞状细胞癌伴和不伴淋巴细胞性甲状腺炎(LT)患者的临床特征和疾病分期。材料和方法我们回顾了英文文献中关于原发性甲状腺鳞状细胞癌的报道。结果和结论我们纳入了46篇论文,其中包括17例原发性甲状腺鳞状细胞癌合并LT和77例原发性甲状腺鳞状细胞癌不合并LT。两组之间淋巴结转移和局部侵袭率没有差异。在LT患者中没有远处转移,在13例(16.9%)无LT患者中观察到远处转移。无LT患者的晚期疾病(IV期A- b - c)比例高于LT患者(p < 0.05)。原发性甲状腺鳞状细胞癌合并淋巴细胞转移的患者比无淋巴细胞癌的患者有更低的肿瘤淋巴结转移分期和远处转移的频率。淋巴细胞浸润似乎限制了鳞状细胞癌的肿瘤生长和远处转移。
{"title":"Less aggressive disease in patients with primary squamous cell carcinomas of the thyroid gland and coexisting lymphocytic thyroiditis","authors":"M. Aşık, E. Binnetoğlu, H. Şen, F. Gunes, A. Muratlı, D. Kankaya, F. Uysal, M. Şahin, K. Ukinç","doi":"10.5114/wo.2015.53372","DOIUrl":"https://doi.org/10.5114/wo.2015.53372","url":null,"abstract":"Aim of the study Primary squamous cell carcinoma (SCC) of the thyroid gland is extremely rare. Infrequently, primary SCC of the thyroid gland is accompanied by other thyroid diseases such as Hashimoto's thyroiditis (HT). Recently, studies have demonstrated that differentiated thyroid cancer with coexisting HT has a better prognosis. However, the prognosis of patients with primary SCC of the thyroid gland and coexistent HT has not been clearly identified. We compared the clinical characteristics and disease stages of patients with primary SCC with and without lymphocytic thyroiditis (LT). Material and methods We reviewed reports of primary SCC of the thyroid gland published in the English literature. Results and conclusions We identified 46 papers that included 17 cases of primary SCC of the thyroid gland with LT and 77 cases of primary SCC of the thyroid gland without LT. Lymph node metastasis and local invasion rates did not differ between these two groups. Distant metastases were absent in patients with LT, and were observed in 13 (16.9%) patients without LT. A greater proportion of patients without LT had advanced stage disease (stage IV A-B-C) than patients with LT (p < 0.05). Patients with primary SCC of the thyroid gland and coexisting LT had lower tumour-node-metastasis stage and frequency of distant metastasis than those without LT. Lymphocytic infiltration in patients with SCC appears to limit tumour growth and distant metastases.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"34 19","pages":"458 - 461"},"PeriodicalIF":0.0,"publicationDate":"2015-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91439021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Contemporary Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1